Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review.

Daniel AtwineMaryline BonnetAnne-Marie Taburet

Published in: British journal of clinical pharmacology (2018)

Anti-TB drug coadministration minimally affect the EFV exposure, efficacy and safety among TB-HIV coinfected African and Asian patients. This supports the current 600 mg EFV dosing when coadministered with anti-TB drugs.

Keyphrases

human immunodeficiency virus
antiretroviral therapy
end stage renal disease
mycobacterium tuberculosis
hiv infected
ejection fraction
hepatitis c virus
newly diagnosed
chronic kidney disease
prognostic factors
hiv aids
hiv positive
risk factors
drug induced
pulmonary tuberculosis
replacement therapy